Product/Composition:- | Ambrisentan tablets |
---|---|
Strength:- | 5 mg and 10 mg |
Form:- | Tablets |
Reference Brands:- | Letairis®(US & EU); Volibris®(EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Ambrisentan is an endothelin receptor antagonist that blocks endothelin-1, a substance that constricts blood vessels. It relaxes pulmonary arteries, decreasing blood pressure. Benefits include improved exercise capacity, symptom relief, and slowed disease progression in pulmonary arterial hypertension patients, enhancing quality of life.
Ambrisentan tablets, marketed as Letairis® and Volibris®, are approved in the US and EU for pulmonary arterial hypertension (PAH). Regulatory dossiers include comprehensive clinical trial data, manufacturing standards, and safety profiles, supporting approval by the FDA and EMA. These dossiers demonstrate Ambrisentan’s efficacy in improving exercise capacity and reducing PAH symptoms. Available in 5 mg and 10 mg tablets, dosing can be tailored to patient response. For detailed insights on regulatory processes, dossier submissions, and market approvals in the EU and US, visit PharmaTradz, your trusted source for pharmaceutical regulatory insights and industry updates.